Hen.Wa
HEN.WA operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, primarily generating revenue through product sales and research activities.
Business. HEN.WA operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, primarily generating revenue through product sales and research activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
HEN.WA operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, primarily generating revenue through product sales and research activities.
HEN.WA maintains a conservative capital structure with a low debt-to-equity ratio of 0.01, indicating minimal reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.27, suggesting it can cover its short-term obligations but with limited buffer. Despite a negative operating cash flow of -1,130,710, the company has a small positive free cash flow of 50,300, which may support limited reinvestment or shareholder returns.
Profitability metrics for HEN.WA are modest, with a return on equity of 0.001 and a return on assets of 0.0008, both significantly below the industry median for biotechnology and medical research firms. The company's net income of 18,850 is a small fraction of its operating income of 1,587,050, indicating high operating expenses or non-operating costs.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, suggesting potential exposure to regional market risks. This lack of diversification could amplify the impact of any adverse developments in its primary market.
Looking ahead, HEN.WA's growth trajectory appears constrained, with no significant revenue growth expected in the next fiscal year. The company's capital expenditure of -45,000 suggests a reduction in investment, which may limit future growth potential. The company's operating cash flow remains negative, which could hinder its ability to fund expansion or R&D initiatives.
Risk factors for HEN.WA include its medium liquidity risk, as indicated by the current ratio and negative net cash position after subtracting total debt. The company's dilution risk is low, with no near-term pressure from share issuance or convertible instruments. However, the absence of disclosed risk factors in recent filings does not preclude the presence of unquantified risks.
Recent events, including the latest financial filing, show a stable but unremarkable performance. The company has not disclosed any material events or strategic shifts in its most recent reports. This suggests a continuation of its current business model without significant innovation or disruption.
- HEN.WA maintains a low debt-to-equity ratio, indicating a conservative capital structure.
- The company's profitability metrics are below industry medians, suggesting operational inefficiencies.
- Revenue is concentrated in a single segment, increasing exposure to market-specific risks.
- Growth prospects are limited, with no significant capital expenditure or revenue growth expected.
- Liquidity is medium, with a current ratio of 1.27 and negative net cash after debt.
- Dilution risk is low, with no near-term pressure from share issuance.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- HEN.WA Market data — financials · 2026-05-28